Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Wave Therapeutics (WVE) Up on Update From Huntington's Study
12:48pm, Wednesday, 21'st Sep 2022
Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.
Why Wave Life Sciences Was Zooming Higher Today
03:18pm, Thursday, 11'th Aug 2022
The company says it has enough dosh on hand to carry it through this and next year.
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2022 Results - Earnings Call Transcript
01:25pm, Thursday, 11'th Aug 2022
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
08:30am, Wednesday, 25'th May 2022
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2022 Results - Earnings Call Transcript
02:52pm, Thursday, 12'th May 2022
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Of
Wave Life Sciences to Present at Upcoming Investor Conferences
08:30am, Tuesday, 10'th May 2022
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
08:30am, Thursday, 05'th May 2022
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
08:30am, Tuesday, 19'th Apr 2022
CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl
Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications
12:22pm, Monday, 04'th Apr 2022
Wave Life Sciences Ltd's (NASDAQ: WVE) FOCUS-C9 study of WVE-004 shows reductions of poly(GP) dipeptide repeat proteins in cerebrospinal fluid (CSF) with low, single doses of WVE-004. The Phase 1
Wave Life Sciences to Present at Stifel 2022 CNS Days
08:30am, Monday, 21'st Mar 2022
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
04:14pm, Monday, 07'th Mar 2022 GlobeNewswire
Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript
12:56pm, Thursday, 03'rd Mar 2022
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript
Wave Life Sciences GAAP EPS of -$0.61 misses by $0.06, revenue of $1.76M misses by $11.98M
12:34pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Wave Life Sciences press release (WVE): Q4 GAAP EPS of -$0.61 misses by $0.06.Revenue of $1.76M (-81.4% Y/Y) misses by $11.98M.
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
12:30pm, Thursday, 03'rd Mar 2022 GlobeNewswire
Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
10:45am, Thursday, 03'rd Mar 2022
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -29.79% and 90.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
